Introduction
The unprecedented outbreak of Ebola (now referred to as Ebola virus disease, or EVD) currently unfolding in West Africa has created challenges for not only the immediately affected countries but also for global organizations, including an emergent need to cope with the business ramifications of having potentially exposed personnel. Policies and procedures (P&Ps) may need to be clarified or created. We offer here a framework that can help guide that process, broadly organized into issues related to travel, the worksite (in countries not directly involved in the Ebola outbreak), and communication.
Background
Ebola virus was isolated from the first identified outbreak in Zaire (now the Democratic Republic of the Congo) in 1976.
Its structure makes it relatively fragile on environmental surfaces. The likely natural reservoir host is bats, which are widespread across Africa. While the bats are unaffected by the virus, infection carries high mortality for other species, including primates (both human and non-human). Index cases of human outbreaks are presumed to result from contact with infected animals (bites from or consumption of ). Further cases result from human-to-human transmission (close contact with symptomatic individuals or those that have died, or exposure to their body fluids).
In the initial Zaire outbreak, 318 people were infected and 280 (88%) died; the maximum incubation period was 21 days. 1 Fever and massive hemorrhage with multiple organ failure and circulatory collapse were the hallmarks. Fortunately, by mid-November the number of new cases had fallen. We hope that the period of explosive spread is ending, but no country is safe in today's world of globe-spanning airline networks. Ebola was even imported to the United States, with cases of symptomatic EVD and limited local spread. 4 The failure to correctly respond to one patient's first presentation and the subsequent transmission of Ebola to two nurses caring for him reflect at a minimum the failure of execution of P&Ps directed at preventing those specific occurrences. P&Ps alone are not enough: they must be communicated, understood, and practiced.
Copious bleeding is less common than in previous outbreaks, and unfortunately the most common presenting symptoms are nonspecific (fever, fatigue, nausea and vomiting, headache, and abdominal pain). 5 Fortunately, Ebola is actually much less contagious than mumps (one-fifth as easily transmissible) or measles (one-ninth). 6 The two US EVD patients who died were both very ill when medical treatment was initiated. Two deaths are few in contrast to the CDC estimates of 3,000 to 49,000 US deaths annually from seasonal influenza. 7 CDC has recently promulgated epidemiologic risk factors for EVD exposure (Box 1). Based on these categories, CDC recommends the actions presented in Box 2. Active monitoring requires the state or local public health authority to check daily with potentially exposed individuals to assess for the presence of symptoms and fever (checked by the individual twice daily). Direct active monitoring requires that at least one of those daily assessments be performed in person by public health employees.
Policy Framework
As an international organization with employees and consultants traveling into, within, and out of Africa every day, RTI is confronted daily with operational issues that have required the clarification or development of numerous P&Ps. individuals, as we assume that state and/or local public health officials will mandate the course of action for travelers with symptoms consistent with EVD.
Using this framework, RTI developed P&Ps to deal with Ebola issues. We will continue to actively monitor the international EVD situation as it evolves, review updated information from CDC and other relevant resources, and revise our policies as needed.
To ensure that staff are asymptomatic and do not present with any special Ebola risk factors, all individuals who have traveled from a country with ongoing outbreaks of EVD, such as Liberia, Guinea, Sierra Leone, or Mali, will be required to debrief upon their arrival with a member of RTI's International Security Team. In addition, employees planning travel to a country with ongoing outbreaks of EVD, such as Liberia, Guinea, Sierra Leone, or Mali-regardless of whether such travel is business or personal-will be required to notify RTI's International Security Team of such travel plans in advance.
We are attempting to ensure that on their exit from these countries, employees' first leg of travel is to a non-African location, preferably London. RTI has a physical presence in England from which we may be able to offer support to a quarantined individual, and also English is the language that would be used in public health interactions (with individuals performing screening and health care workers, on forms, etc.).

Travel-Related Issues
•• Countries of concern-how are those determined, and how often is that evaluated? (e.g., http://www.cdc.gov/travel/notices)
• -Do travelers to these countries receive specific information (e.g., on EVD and risk avoidance, what to do if they become ill) or materials (e.g., international phones) pre-travel? If so, how are these chosen and/or created?
-Do local individuals traveling from these countries receive materials (e.g., thermometers) or information specific to potential restrictions (e.g., mandatory testing, monitoring, quarantine) at their connecting points or destinations? If so, how are these chosen and/or created? These are challenging times for global organizations. Media coverage suggests that some individuals view Ebola as a force of mythic malevolence, when in fact infection control specialists have known for almost 40 years the procedures by which to manage it. By guiding our business actions in accordance with the science but with a sensibility to employee concerns, we hope to avoid implementing unnecessary procedures while still providing a work environment viewed as safe by all employees. RTI's Center for Communication Science is also partnering with CDC to address some of the myriad public perception challenges inherent with emergent global diseases like this one. 10 
